Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Non Operating Income (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Non Operating Income for 15 consecutive years, with -$23337.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 28.53% year-over-year to -$23337.0, compared with a TTM value of $45066.0 through Sep 2025, up 127.01%, and an annual FY2024 reading of -$147499.0, up 54.89% over the prior year.
  • Non Operating Income was -$23337.0 for Q3 2025 at China Pharma Holdings, down from $123753.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $123753.0 in Q2 2025 and bottomed at -$332029.0 in Q4 2021.
  • Average Non Operating Income over 5 years is -$71782.4, with a median of -$64265.0 recorded in 2021.
  • The sharpest move saw Non Operating Income tumbled 208.77% in 2021, then surged 365.51% in 2025.
  • Year by year, Non Operating Income stood at -$332029.0 in 2021, then surged by 71.34% to -$95172.0 in 2022, then skyrocketed by 49.86% to -$47722.0 in 2023, then surged by 40.5% to -$28396.0 in 2024, then grew by 17.82% to -$23337.0 in 2025.
  • Business Quant data shows Non Operating Income for CPHI at -$23337.0 in Q3 2025, $123753.0 in Q2 2025, and -$26954.0 in Q1 2025.